寿仙谷成立于1997年3月3日，于2017年5月10日在上海证券交易所上市，注册地址和办公地址均位于浙江 省。公司是国内灵芝、铁皮石斛行业的领军企业，拥有全产业链优势和独家去壁技术，投资价值显著。 寿仙谷主要从事灵芝、铁皮石斛等名贵中药材的品种选育、栽培、加工及销售。所属申万行业为医药生物 - 中药Ⅱ - 中药Ⅲ，所属概念板块有中药、工业大麻、医药电商核聚变、超导概念、核电。 经营业绩：营收行业第58，净利润第38 2025年三季度，寿仙谷营业收入4.3亿元，在行业69家企业中排名58。行业第一名白云山营收616.06亿元， 第二名云南白药306.54亿元，行业平均数为37.55亿元，中位数为14.62亿元。当期净利润7634.62万元，行 业排名38，行业第一名云南白药净利润47.89亿元，第二名白云山33.98亿元，行业平均数为4.47亿元，中位 数为8367.73万元。 资产负债率低于同业平均，毛利率高于同业平均 偿债能力方面，2025年三季度寿仙谷资产负债率为26.69%，去年同期为26.93%，低于行业平均的32.81%。 从盈利能力看，2025年三季度毛利率为79.06%，去年同期为80.52%， ...

Core Viewpoint - Zhejiang Shouxiangu Pharmaceutical Co., Ltd. reported a revenue increase of 8.51% year-on-year for Q3 2025, demonstrating resilience in a challenging consumer market [1][2] Financial Performance - The company achieved a revenue of 130 million yuan in Q3 2025, with a net cash flow from operating activities of 20.94 million yuan, reflecting a 51.24% increase year-on-year [1] - Net profit attributable to shareholders decreased due to increased R&D investments [1] Business Strategy - The company is focusing on "marketing-driven enterprise" strategies, enhancing marketing channels, brand building, and digital marketing innovations [2] - Shouxiangu is expanding its market presence through a dual-channel approach, combining specialty store systems with traditional pharmacy channels [1][2] Product Development - The company has optimized its product matrix, launching new products such as Shouxiangu Blue and Shouxiangu Red, which cater to modern consumer trends [1][2] - Shouxiangu has established a multi-category matrix for health food products, including new beverages and solid drinks, positioning this segment as a key growth area [2] R&D Investment - R&D expenses reached 42.09 million yuan in the first three quarters, marking a 32.32% increase year-on-year, supporting the development of innovative products [3] - The company has initiated 92 research projects, including 56 collaborative projects with academic institutions, enhancing its competitive edge in the market [3] Industry Outlook - The market for health food products, particularly those derived from traditional Chinese medicine, is expected to grow due to rising health awareness and the emergence of younger consumer demographics [2][3]

Core Viewpoint - Shouxiangu (603896.SH) reported a decline in institutional ownership in its Q3 2025 report, with a total of 3 institutional investors holding 59.204 million shares, representing 29.86% of the total share capital, a decrease of 0.98 percentage points from the previous quarter [1] Institutional Ownership - As of October 28, 2025, three institutional investors disclosed their holdings in Shouxiangu, with a combined ownership of 59.204 million shares, accounting for 29.86% of the total share capital [1] - The institutional ownership percentage decreased by 0.98 percentage points compared to the previous quarter [1] Public Fund Holdings - One public fund, Rongtong Health Industry Flexible Allocation Mixed A/B, increased its holdings in the current period, contributing to a slight rise in the overall public fund ownership [1] - A total of 28 public funds that were previously disclosed did not report their holdings this quarter, including notable funds such as Dongfanghong Zhiyuan Three-Year Holding Mixed and Huatai-PineBridge Healthcare Mixed [1]

Core Viewpoint - The company, Zhejiang Shouxiangu Pharmaceutical Co., Ltd., has released its quarterly report, ensuring the accuracy and completeness of the financial information presented [2][3]. Financial Data Summary - The third-quarter financial statements have not been audited [3]. - The report includes major accounting data and financial indicators, with the reporting period defined as the three months from the beginning to the end of the quarter [3]. - A retrospective adjustment has been made due to a business combination with a subsidiary, impacting the financial data for the previous year [4]. Non-Recurring Gains and Losses - The company has identified significant non-recurring gains and losses, which are detailed in the report [5]. Shareholder Information - The report includes information on the total number of ordinary shareholders and the top ten shareholders, although there are no changes reported in the shareholding structure due to securities lending activities [7]. Financial Statements - The consolidated balance sheet and profit and loss statement for the period from January to September 2025 have been prepared, with the audit type noted as unaudited [9]. - The net profit of the acquired entity prior to the merger was reported as 63,703.61 yuan, while the previous year's net profit was -701,132.81 yuan [9].

Core Viewpoint - Shouxiangu (603896.SH) reported a decline in both revenue and net profit for the first three quarters of the year, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first three quarters was 430 million yuan, a year-on-year decrease of 10.23% [1] - The net profit attributable to shareholders was 76.34 million yuan, down 33.47% year-on-year [1] - The net profit excluding non-recurring gains and losses was 42.29 million yuan, reflecting a significant decline of 54.48% year-on-year [1]

浙江寿仙谷医药股份有限公司 2025 年第三季度报告 证券代码：603896 证券简称：寿仙谷 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李明焱、主管会计工作负责人祝彪及会计机构负责人（会计主管人员）孙海峰保证季 度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 1 / 15 浙江寿仙谷医药股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 项目 本报告期 上年同期 本报告期比上 年同期增减变 动幅度(%) 年初至报告期 末 上年同期 年初至报告 期末比上年 同期增减变 动幅度(%) 调整前 调整后 调整后 调整前 调整后 调整后 营业收入 130,454,533.70 ...

Core Insights - The company Shouxiangu (603896.SH) reported a revenue of 430 million yuan for the first three quarters of 2025, representing a year-on-year decline of 10.23% [1] - The net profit attributable to the parent company was 76.34 million yuan, down 33.47% year-on-year [1] - The net profit after deducting non-recurring items was 42.29 million yuan, reflecting a significant decrease of 54.48% year-on-year [1] - The basic earnings per share stood at 0.39 yuan [1]

Core Insights - The article highlights the increasing trend of A-share listed companies in China engaging in physical rewards for shareholders, enhancing investor relations and creating a unique investment-consumption ecosystem [1][4]. Group 1: Company Activities - Over 30 listed companies have participated in shareholder reward activities since 2025, offering products, discount coupons, and tourism rights to investors [1][4]. - Companies like Tianyu Bio, Huasheng Co., and Beiqing Song have announced various forms of physical rewards, aiming to deepen shareholder experience with core products and strengthen their value recognition [2][3]. - The second "Listed Company Shareholder Festival" organized by Tonghuashun attracted nearly 100 companies, providing a wide range of gifts including electronics, food, and cosmetics to shareholders [3]. Group 2: Policy and Market Trends - The trend of physical rewards aligns with the China Securities Regulatory Commission's policy to enhance investor protection and improve returns for shareholders [4]. - The increasing participation of companies in physical reward activities indicates a shift from individual cases to a systematic approach in investor relations management [4]. - The practice of physical rewards is expected to become a significant indicator of corporate governance and market competitiveness in the future [4].

Core Viewpoint - The company, Zhejiang Shouxiangu Pharmaceutical Co., Ltd., has completed the registration change and amendment of its articles of association following the approval of its board and supervisory meetings [1] Group 1 - The company held its fifth board and supervisory meetings on August 27, 2025, where it approved the proposal to change its registered capital and cancel the supervisory board [1] - The proposal was subsequently approved at the first extraordinary general meeting of shareholders held on September 18, 2025 [1] - The company has completed the business registration change and obtained a new business license from the Zhejiang Provincial Market Supervision Administration [1]

浙江寿仙谷医药股份有限公司 章 程 二〇二五年九月（修订） | 第一章 | 总则 1 | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 2 | | | 第三章 | 股份 3 | | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 5 | | 第四章 | 股东和股东会 6 | | | 第一节 | 股东的一般规定 | 6 | | 第二节 | 控股股东和实际控制人 | 10 | | 第三节 | 股东会的一般规定 | 11 | | 第四节 | 股东会的召集 | 14 | | 第五节 | 股东会的提案与通知 | 15 | | 第六节 | 股东会的召开 | 17 | | 第七节 | 股东会的表决和决议 | 20 | | 第五章 | 董事和董事会 24 | | | 第一节 | 董事的一般规定 | 24 | | 第二节 | 董事会 | 28 | | 第三节 | 独立董事 | 32 | | 第四节 | 董事会专门委员会 | 35 | | 第六章 | 高级管理人员 37 | | | 第七章 | 财务会计制度、利润分配和审计 39 | | ...